PCM
NVIV

Perkins Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Perkins Capital Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$35K Sell
833
-667
-44% -$94.4K 0.04% 96
2019
Q4 		$253K Buy
+1,500
New +$373K 0.23% 84

Other funds holding NVIV

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Perkins Capital Management's NVIV Position: Q1 2020 in Review

Perkins Capital Management reduced its InVivo Therapeutics Holdings Corp (NVIV) stake by 44% in Q1 2020, selling an estimated $94.4K and leaving 833 shares worth $35K. The position accounts for 0.04% of the portfolio, ranked #96.

Perkins Capital Management first reported a position in NVIV in Q4 2019 and has held it in 2 quarters since. The position peaked at $253K in Q4 2019. 10 funds tracked by Wall St. Rank hold NVIV as of Q1 2020.

  • Perkins Capital Management held 833 shares of InVivo Therapeutics Holdings Corp worth $35K as of Q1 2020.
  • Perkins Capital Management sold 667 InVivo Therapeutics Holdings Corp shares in Q1 2020, an estimated $94.4K.
  • InVivo Therapeutics Holdings Corp made up 0.04% of Perkins Capital Management's portfolio in Q1 2020, its #96 holding.
  • Perkins Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q4 2019 and has held it in 2 quarters since.
  • Perkins Capital Management's InVivo Therapeutics Holdings Corp position peaked at $253K in Q4 2019.
  • 10 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2020.

Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.